MABT’s current focus is to bring new treatment options for hard-to-treat bacterial infections to market. These infections have high morbidity and mortality rates, often caused by bacteria that are partially or completely resistant to current antibiotics. IMT504 offers a powerful ‘antibiotic alternative’. We also focus on certain viruses that have incredibly high mortality rates, like rabies, that until now have few or no effective treatment options available for patients.
MABT is leveraging several FDA regulatory pathways to rapidly accelerate the time to market. MABT expects to begin final human testing (Phase 3) for rabies in 2017 with the goal of having IMT504 on the commercial market by 2019.
This first FDA approval will serve as a ‘regulatory accelerator’ to drive the larger commercial anti-bacterial market indications, with the goal of FDA approval of this novel antibiotic alternative by 2020/2021.